Literature DB >> 23666925

Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis.

Rebecca Quiñones1, Gabrielle A Morgan, Maria Amoruso, Regina Field, Chiang-Ching Huang, Lauren M Pachman.   

Abstract

OBJECTIVE: To test 4-year-olds, using 14 maneuvers of the Childhood Myositis Assessment Scale (CMAS), comparing healthy children with those with juvenile dermatomyositis (DM).
METHODS: Healthy 4-year-olds (n = 28) completed the CMAS. Their scores were compared with children with juvenile DM (n = 18) who had a muscle Disease Activity Score (DAS-M) of 0.
RESULTS: The healthy children achieved a mean ± SD CMAS score of 46.6 ± 2.3 (interquartile range 46-47). There were no significant differences between boys and girls, and the scores were not significantly associated with height or weight. The greatest variation involved items that assessed endurance. Item 1, neck raise, yielded a mean ± SD score of 28.2 ± 19.3 seconds, with a mean ± SD CMAS score of 2.5 ± 0.9 (maximum score 5). Item 3, leg lift, yielded a mean ± SD score of 55.5 ± 37.3 seconds, with a mean ± SD CMAS score of 3.1 ± 1.1 (maximum score 5). Item 5, sit-ups maneuver, yielded a mean ± SD score of 5.3 ± 1.1 sit-ups. Almost identical data were obtained for the 18 treated children with juvenile DM who had normal strength on the DAS-M.
CONCLUSION: Healthy children ages 4 years do not achieve the total CMAS score of 52 attained by older children. Both boys and girls were remarkably consistent, with a mean CMAS score of 46.6. Children ages 4 years with juvenile DM with a DAS-M of 0 also achieved a CMAS score of 46.6. We conclude that half of 4-year-old children achieve a mean CMAS score of 46 or 47, not a total CMAS score of 52, suggesting that weakness may be overdiagnosed in 4-year-olds with an inflammatory myopathy.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 23666925     DOI: 10.1002/acr.22041

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  7 in total

1.  Serum protein biomarkers for juvenile dermatomyositis: a pilot study.

Authors:  Shefa M Tawalbeh; Wilfredo Marin; Gabrielle A Morgan; Utkarsh J Dang; Yetrib Hathout; Lauren M Pachman
Journal:  BMC Rheumatol       Date:  2020-10-01

2.  Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response.

Authors:  Butsabong Lerkvaleekul; Saskia R Veldkamp; M Marlot van der Wal; Ellen J H Schatorjé; Sylvia S M Kamphuis; J Merlijn van den Berg; Petra C E Hissink Muller; Wineke Armbrust; Sebastiaan J Vastert; Judith Wienke; Marc H A Jansen; Annet van Royen-Kerkhof; Femke van Wijk
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

3.  Juvenile Dermatomyositis Magnetic Resonance Imaging Score (JIS) does not correlate with criteria for clinically inactive disease: a single-centre retrospective evaluation.

Authors:  Kapil Gargh; Eslam Al-Abadi; Samantha Low; Kathryn Harrison; William Coles; Penny Davis; Karl Johnson
Journal:  Rheumatol Int       Date:  2021-11-18       Impact factor: 3.580

4.  Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive.

Authors:  Elisha D O Roberson; Rosana A Mesa; Gabrielle A Morgan; Li Cao; Wilfredo Marin; Lauren M Pachman
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

5.  British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy.

Authors:  Alexander G S Oldroyd; James B Lilleker; Tania Amin; Octavio Aragon; Katie Bechman; Verna Cuthbert; James Galloway; Patrick Gordon; William J Gregory; Harsha Gunawardena; Michael G Hanna; David Isenberg; John Jackman; Patrick D W Kiely; Polly Livermore; Pedro M Machado; Sue Maillard; Neil McHugh; Ruth Murphy; Clarissa Pilkington; Athiveeraramapandian Prabu; Phoebe Rushe; Stefan Spinty; Joanne Swan; Hasan Tahir; Sarah L Tansley; Paul Truepenny; Yvonne Truepenny; Kishore Warrier; Mark Yates; Charalampia Papadopoulou; Neil Martin; Liza McCann; Hector Chinoy
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

Review 6.  Consensus-based recommendations for the management of juvenile dermatomyositis.

Authors:  Felicitas Bellutti Enders; Brigitte Bader-Meunier; Eileen Baildam; Tamas Constantin; Pavla Dolezalova; Brian M Feldman; Pekka Lahdenne; Bo Magnusson; Kiran Nistala; Seza Ozen; Clarissa Pilkington; Angelo Ravelli; Ricardo Russo; Yosef Uziel; Marco van Brussel; Janjaap van der Net; Sebastiaan Vastert; Lucy R Wedderburn; Nicolaas Wulffraat; Liza J McCann; Annet van Royen-Kerkhof
Journal:  Ann Rheum Dis       Date:  2016-08-11       Impact factor: 19.103

7.  Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy.

Authors:  Lauren M Pachman; Brian E Nolan; Deidre DeRanieri; Amer M Khojah
Journal:  Curr Treatm Opt Rheumatol       Date:  2021-02-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.